Business Context and Reporting Period
This Form 8-K Current Report was filed by Bristol-Myers Squibb Company on May 7, 2008, covering events occurring on May 1 and May 2, 2008. The filing primarily announces a material definitive agreement to divest a business unit and references a prior debt issuance.
Key Financial Metrics and Transaction Details
- Transaction Value: $4.1 billion in cash for the sale of the ConvaTec business.
- Buyer: Cidron Healthcare Limited, an affiliate of Nordic Capital Fund VII and Avista Capital Partners.
- Debt Issuance (Historical Reference): The filing references a May 1, 2006 offering of $600 million in 5.450% Notes due 2018 and $1 billion in 6.125% Notes due 2038.
- Price Adjustment Mechanism: The final purchase price is subject to adjustment based on closing working capital and 2007 EBITDA variances. A maximum downward adjustment of $115 million applies if audited 2007 EBITDA is lower than unaudited figures by more than $1.5 million.
- Termination Threshold: The Buyer may terminate the agreement if audited 2007 EBITDA is less than unaudited 2007 EBITDA by more than $10 million.
Material Changes and Transaction Structure
The Company entered into a Stock and Asset Purchase Agreement to sell its ConvaTec business. The transaction involves the transfer of outstanding capital stock of certain indirect subsidiaries and specified assets and liabilities. The sale is expected to close in the third quarter of 2008, pending regulatory approvals and the delivery of audited 2007 financial statements. The Buyer has secured fully committed equity and debt financing with no material conditions other than those in the agreement.
Outlook, Risks, and Covenants
- Closing Conditions: The transaction is contingent on customary regulatory approvals (U.S. and EU), delivery of audited financials, and satisfaction of other closing conditions.
- Non-Compete Covenant: For three years following the closing, Bristol-Myers Squibb is prohibited from engaging in any business that competes materially with the ConvaTec business, subject to exceptions.
- Indemnification: Both parties have agreed to indemnify each other for losses arising from breaches of the agreement and certain other liabilities.
- Transitional Services: The parties agreed to enter into a transitional services agreement at closing.
Key Facts for Investor Verification
- Verify the final purchase price adjustment based on the delivery of audited 2007 EBITDA figures.
- Monitor the status of regulatory approvals in the United States and European Union required for the third-quarter 2008 closing.
- Confirm the impact of the $4.1 billion cash inflow on the Company's liquidity and capital structure upon closing.
- Review the specific exceptions to the three-year non-compete covenant regarding the ConvaTec business.